Abstract:Abstract Background Predicting, preventing, and treating post-COVID condition (PCC; “Long COVID) is challenging due to a limited understanding of PCC mechanisms. To address this, we analyzed whole blood transcriptomic data using machine learning to identify candidate gene and gene expression pathways associated with the development of PCC. Figure 1 (A) Clinical and demographic characteristics of 222 military health system beneficiaries (COVI D, no PCC: SARS-CoV-2 positive subjects reported no or mild symptoms on 6-month survey; COVID, PCC: SARS-CoV-2 positive subjects reported moderate to severe symptoms on 6-month survey; and Control: SARS-CoV-2 negative subjects), (B) AUROC indicates the ability of leading genes (measured early after infection, TSSK4, TUFT1, and XBP1; which have known association with pulmonary fibrosis, lung cancer, and lymphoma, respectively) which can predict which participants develop PCC versus those who do not, and (C) Identification of biomarker candidates for PCC based on machine learning algorithms. Statistical significance was determined by Mann-Whitney U test. Asterisks indicate statistical significance: ns: p > 0.05, *: p ≤ 0.05 Methods The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a longitudinal cohort study exploring the impact of SARS-CoV-2 infection in military health system beneficiaries. We collected demographic and clinical data through surveys, interviews and medical record reviews. We conducted transcriptome profiling (bulk RNA-seq) on early post-infection whole blood samples from unvaccinated individuals with and without PCC at 6-months, as well as uninfected, unvaccinated controls. These three groups were matched on sex, age, and comorbidities. We identified transcriptomic signatures associated with group classes using t-tests with correction for multiple comparisons. Molecular signatures and candidate markers for PCC were developed using gene set enrichment analysis (GSEA) and machine learning, including random forest (RF) and support vector machine (SVM) methods. Results Out of the 5289 SARS-CoV-2 positive Military Health System beneficiaries enrolled in EPICC, 814 participants had at least one sample with blood transcriptomic profiling data. Among these, 171 unvaccinated, SARS-CoV-2 positive participants completed a 6-month follow up survey and were included in the analysis. Ninety-one percent did not report any chronic symptoms, while 8% reported moderate to severe symptoms at six months and were classified as PCC group. A control group of 51 participants was also identified. Machine learning approaches (RF: AUROC = 0.90, CI = 0.79 to 1; and SVM: AUROC = 0.89, CI = 0.76 to 1) identified three candidate biomarkers (Figure 1), including TSSK4, TUFT1, and XBP1 genes, which could be a predictive or mechanistic marker for PCC with further validation. Conclusion Our study demonstrates the potential of using machine learning to translate transcriptomic data into precision medicine applications, specifically for predicting the development of PCC after COVID-19. Disclosures Mark P. Simons, PhD, AstraZeneca: The IDCRP and HJF were funded to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial as part of US Govt COVID Response Timothy Burgess, MD, MPH, AstraZeneca: The IDCRP and the Henry M. Jackson Foundation (HJF) were funded to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial Simon Pollett, MBBS, AstraZeneca: The IDCRP and the Henry M. Jackson Foundation (HJF) were funded to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial

Blood DNA methylation in post-acute sequelae of COVID-19 (PASC): a prospective cohort study

Defining post-acute COVID-19 syndrome (PACS) by an epigenetic biosignature in peripheral blood mononuclear cells

Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection

Identification of Whole-Blood DNA Methylation Signatures and Rules Associated with COVID-19 Severity

Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review

Single‐cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms

POST-ACUTE SEQUELAE OF COVID-19: CHARACTERIZATION, COMORBIDITIES, AND BIOMARKERS IN A DIVERSE COHORT

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Epigenetic patterns, accelerated biological aging, and enhanced epigenetic drift detected 6 months following COVID-19 infection: insights from a genome-wide DNA methylation study

Genome-Wide Analysis of DNA Methylation and Acute Coronary Syndrome

Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Multiple early factors anticipate post-acute COVID-19 sequelae

Altered DNA methylation pattern contributes to differential epigenetic immune signaling in the upper respiratory airway of COVID-19 patients

Integration of Genome-Wide DNA Methylation and Transcription Uncovered Aberrant Methylation-Regulated Genes and Pathways in the Peripheral Blood Mononuclear Cells of Systemic Sclerosis

Genome-wide DNA Methylome Alterations in Acute Coronary Syndrome

Early biological markers of post-acute sequelae of SARS-CoV-2 infection

1352. A Precision Medicine Approach to Predicting “Long COVID” through Machine Learning Analysis of Whole Blood Transcriptome Data

Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

Bulk RNA sequencing for analysis of post COVID-19 condition in adolescents and young adults

Genome-wide DNA methylation profiling in blood reveals epigenetic signature of incident acute coronary syndrome

Identification of key gene expression associated with quality of life after recovery from COVID-19